Lanean...
Oncogenic KRAS confers chemoresistance by upregulating NRF2
Oncogenic KRAS mutations found in 20–30% of all non-small cell lung cancers (NSCLC) are associated with chemoresistance and poor prognosis. Here we demonstrate that activation of the cell protective stress response gene NRF2 by KRAS is responsible for its ability to promote drug resistance. RNAi-med...
Gorde:
| Argitaratua izan da: | Cancer Res |
|---|---|
| Egile Nagusiak: | , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2014
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4268230/ https://ncbi.nlm.nih.gov/pubmed/25339352 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-1439 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|